TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03294785

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chuna manual therapy
Description: Chuna is a Korean manual therapy that has absorbed and incorporated aspects of osteopathic manipulative medicine. Chuna manual therapy utilizes spinal manipulation techniques for joint mobilization including high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement, muscle energy, and fascial techniques.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional medication
Description: Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Physical therapy will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.
Study: NCT00730938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefuroxime
Description: intracameral cefuroxime 0.1 ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: 0.1 ml of Ringers lactate
Study: NCT03760900

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood Stem Cells Therapy
Description: Autologous Umbilical Cord Blood Stem Cells Therapy,the dose is 5×107cells/kg, within 24 hours after birth
Study: NCT02723500

Intervention type: DEVICE
Group type: OTHER
Intervention: Hyperpolarized Xenon MRI
Description: Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
Study: NCT04550598

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tCES
Description: The high definition transcranial electrical stimulation was applied using a 1\*4 ring electrode configuration. The electrode will be applied at the left M1 or contralateral to pain side. The anodal electrode was placed on the C3/C4, and the remaining 4 cathodal electrodes were placed in a radius of approximately 7.5 cm from anode (Cz, F3, T7, and P3 on the left hemisphere or Cz, F4, T8, and P4 on the right hemisphere). Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
Study: NCT03236662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (-)-Epicatechin
Study: NCT04163172

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment of distal humeral fracture with elbow hemiarthroplasty
Description: Latitude anatomical elbow hemiarthroplasty (WRIGHT -Memphis, Tennessee)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment of distal humeral fracture with double plating.
Description: Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States)
Study: NCT01913496

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ebalance
Description: using the ebalance application for 14 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ebalance
Description: using the ebalance application for 14 weeks
Study: NCT03799042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Subjects will wear a 3D glass and watch 3D pictures (or video) of landscapes or tourist sites in Hong Kong.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inter-generation interaction
Description: Secondary school student will play games and chats with secondary school students. Games involve identifying famous landscapes or tourist sites in Hong Kong
Study: NCT01910935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity prescription to develop program in group.
Description: Overall the intervention involves a medical reference in primary care (PHC) to hypertensive patients (during routine consultation) to assist the sports facilities of the same Institute, to develop a group program of physical activity which will last 24 weeks. Led by the trained staff in physical activity to patients with chronic diseases.
Study: NCT00856518

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMST
Description: Pressure threshold device (Expiratory Muscle Strength Trainer) targeted at increase muscle force generation of expiratory and submental muscles.
Study: NCT02128230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: myPRS
Description: Genome expression profiling used to identify high-risk and low-risk multiple myeloma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction 1 - MEL-10+CFZ-TD-PACE
Description: Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days 1, 5, \& 6; MEL 10mg/m2 on day 3; T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 400 mg/m2/d, and E 40 mg/m2/d on days 5-8; G-CSF 10 mcg/kg/day from day 11 through end of Peripheral Blood Stem Cell (PBSC) collection.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until 1st transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)
Description: Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days -5 \& -4; MEL 20 mg/m2/d, T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 100 mg/m2/d, and E 80 mg/m2/d on days -5 \& -2; PBSC transplant on day 0.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until inter-therapy.
Study: NCT00856518

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The same device just like the EMST but does not provide a load on the target muscle group
Study: NCT01458041

Intervention type: DRUG
Intervention: Iloprost (Ilomedin, BAYQ6256)
Description: Prescription and treatment of Iloprost will be decided by physicians
Study: NCT01085994

Intervention type: OTHER
Intervention: Literature search
Description: Literature search followed by systematic review and meta-analysis

Intervention type: OTHER
Intervention: Literature search
Description: Literature search followed by systematic review and meta-analysis
Study: NCT02663401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Front-of-pack labelling 5-CNL
Description: Introduction of the 5-CNL Front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
Study: NCT04751006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gaze Stabilization Exercises
Description: Gaze group performed balance exercises with gaze stability exercise.Gaze stability exercises included two types of exercises vestibular adaptation and substitution exercises. In Adaptation exercises individual need to fixate on a visual target during horizontal and vertical head movement with a purpose of increasing gaze stability and a long term gain to vestibular system. Subsitution exercises are planned to use other eye movement stratigies to substitute vestibular function and sustained visual fixation. During Substitution exercises individual need to perfomed eye head movement between target with a purpose of clear sighting during these tasks. Balance exercises consist of both static and dynamic balance exercises with weekly progression making balance exercises more challenging.

Intervention type: OTHER
Group type: OTHER
Intervention: Balance Training
Description: Participants performed balance training with saccade eye exercises.balance exercises included both static and dynamic balance exercises with a purpose of increasing mobility and stability of a posture by weekly progression. These exercises included standing on firm and foam surface with eyes open or close, heel stand, toe stand, marching on firm surface, forward and backward walking with normal base of support with weekly progression. Each task was performed for 5 repetitions with weekly progression in each task.
Study: NCT03082625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Magnesium
Description: Magnesium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01924949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Ledipasvir (LDV)/sofosbuvir (SOF) 90/400 mg FDC tablet administered orally once daily
Study: NCT02128230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inter-Therapy - MEL-20+CFZ-TD-PACE (75%)
Description: Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 27 mg/m2 on days 1-2; MEL 5 mg/m2/d, T 200 mg/d, D 20 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 75 mg/m2/d, and E 60 mg/m2/d on days 1-4.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until 2nd transplant.
Study: NCT01317277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individualized Texting for Adherence Building (iTAB)
Description: Behavioral: Psychoeducation~Participants will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence.~Behavioral: individualized Texting for Adherence Building (iTAB)~Intervention is designed to send automated text messages to HIV+ persons who are current methamphetamine (METH+) users. Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART medications among HIV+/METH+ persons above and beyond an active comparator group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Behavioral: Psychoeducation~Participants will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence.
Study: NCT02128230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)
Description: Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days -5 \& -4; MEL 20 mg/m2/d, T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 100 mg/m2/d, and E 80 mg/m2/d on days -5 \& -2; PBSC transplant on day 0.~Optional Bridging with T 50mg/d and D 20 mg on day 1-4 every 21 days until consolidation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation - CFZ-TD-PACE
Description: Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), adriamycin (A), cyclophosphamide (C) and etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter.~Regimen: CFZ 27 mg/m2 on days 1-2; T 200 mg/d, D 40 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 300 mg/m2/d, and E 30 mg/m2/d on days 1-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance - CFZ-R(T)-D
Description: Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) and lenalidomide (R) are capsules and dexamethasone (D) is a pill; all will be taken by mouth.~Regimen: For Cycles 1-12 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, \& 22; lenalidomide (R) 15 mg/d on days 1-21. For Cycles 13-24 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, \& 22. T may be substituted for R at 100 mg/day at the treating physician's discretion.
Study: NCT03847675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach out and Read
Description: The intervention group will be viewing a video encouraging to read to their children and giving tips on reading methods, in addition will be given a schematic pamphlet highlighting the importance of reading Arabic to children.~After each visit participants will receive an age appropriate book for their child (a total of 3 books). The first book consist of popular nursery rhymes that are usually sung for younger infants. The choice of the 2 other books is based on recommendations from an early child educator according to age specificity.~Focus group conducted by a qualitative researcher will follow the protocol reported by Richard A. Krueger.
Study: NCT02409654

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: (i) Patient education (ii) Assess individual risk of stroke using the CHADS2 and CHA2DS2VASc score and risk of major bleeding using the HAS-BLED score (iii) Recommendation of evidence-based stroke prevention therapy based on international guidelines (iv) Patient audit and follow-up (v) Patients not on appropriate OAC without adequate explanation will be referred to Cardiology Outpatient Clinic for second opinion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left to the discretion of the attending doctor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine care
Description: The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left to the discretion of the attending doctor.
Study: NCT01805622

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Arm #1, #2, Passive Arm #1, #2
Description: This four-arm cluster randomized trial (five community coalitions plus 1,800 African Americans, 50-74 years of age, who are not current on CRC screening per arm) compares the following implementation strategies: (1) web access to facilitator training materials and toolkits without technical assistance (TA); (2) web access, but with technical assistance (TA); (3) in-person access to facilitator training materials and toolkits without TA and (4) in-person access with TA.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Arm #1, #2, Passive Arm #1, #2
Description: This four-arm cluster randomized trial (five community coalitions plus 1,800 African Americans, 50-74 years of age, who are not current on CRC screening per arm) compares the following implementation strategies: (1) web access to facilitator training materials and toolkits without technical assistance (TA); (2) web access, but with technical assistance (TA); (3) in-person access to facilitator training materials and toolkits without TA and (4) in-person access with TA.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Arm #1, #2, Passive Arm #1, #2
Description: This four-arm cluster randomized trial (five community coalitions plus 1,800 African Americans, 50-74 years of age, who are not current on CRC screening per arm) compares the following implementation strategies: (1) web access to facilitator training materials and toolkits without technical assistance (TA); (2) web access, but with technical assistance (TA); (3) in-person access to facilitator training materials and toolkits without TA and (4) in-person access with TA.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Arm #1, #2, Passive Arm #1, #2
Description: This four-arm cluster randomized trial (five community coalitions plus 1,800 African Americans, 50-74 years of age, who are not current on CRC screening per arm) compares the following implementation strategies: (1) web access to facilitator training materials and toolkits without technical assistance (TA); (2) web access, but with technical assistance (TA); (3) in-person access to facilitator training materials and toolkits without TA and (4) in-person access with TA.
Study: NCT02788097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progesterone supplementation
Description: artificial frozen embryo transfers

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone supplementation
Description: artificial frozen embryo transfers
Study: NCT03467464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Description: The intervention consists of 10 weekly EMDR sessions of 60 minutes and targets stressful daily life (i.e. a situation that caused anger, fear or confusion) events rather than traumatic images from the past. For each session, a standardised EMDR protocol is used that consists of the following consecutive steps: 1) determining and visualising a confusing and/or stressful daily life event that occurred during the past week; 2) formulating a negative and a positive thought based on the chosen event; 3) determining the amount of stress that is evoked by the chosen event; 4) patient focuses on the chosen event while being presented with a distracting stimulus; 5) evaluating the amount of stress that is caused by the chosen event; 6) linking positive thoughts to the negative one when the stress caused by the chosen event does no longer exist; 7) evaluation and closure of session.
Study: NCT01418183

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trigeminal nerve block
Description: 5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trigeminal nerve block
Description: 2.5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Trigeminal nerve block
Description: 5ml Normal saline will be delivered to maxillary and mandibular branches of trigeminal nerve.
Study: NCT03882970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC
Study: NCT01305538

Intervention type: DRUG
Group type: OTHER
Intervention: BMS-954561

Intervention type: DRUG
Group type: OTHER
Intervention: BMS-954561

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study: NCT00133991

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 mcg/kg/day starting on Day 3 after each R-CVP cycle and on Day 6 after HiCy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 on Day 1 and Day 8 of each R-CVP cycle. 375 mg/m\^2 on Day -4 of HiCy and weekly for four weeks after HiCy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1500 mg/m\^2 on Day 1 of each R-CVP cycle. 50 mg/kg/day on Days -3, -2, -1, and 0 of HiCy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 3 g/m\^2 on Day 8 of each cycle of R-CVP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg on Days 1-5 of each cycle of R-CVP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 50 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m\^2 on Day 1 of each cycle of R-CVP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 25 mg four times daily after methotrexate administration. Dosing continues until adequate methotrexate levels are reached.